A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from Bluebird Bio will likely receive an FDA decision by mid-2022. ICER has released an outline of its strategy for the assessment. It […]
Upcoming ICER Webinar Will Discuss Barriers to Fair Access
On December 3rd (12 PM), the Institute for Clinical and Economic Review will host a public webinar detailing the findings of their annual assessment of Barriers to Fair Access in major US payers’ prescription drug coverage policies. Presenters include Sara Edmond, Cat Ahmed, Rebecca Kirch, and […]
Panalgo and HealthEconomics.Com Host Webinar on Successful ICER Strategies
Panalgo and HealthEconomics.Com hosted a webinar detailing strategies that lead to successful evaluation by the Institute for Clinical and Economic Review (ICER). President of HealthEconomics.Com Patti Peeples moderated the session, which included important insights from Center for the Evaluation of […]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic Review (ICER) in its Unsupported Price Increase (UPI) assessments. Payers are increasingly incorporating these ICER reviews in their coverage decision-making […]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and Bristol-Myers Squibb. The drug is used in patients diagnosed with hypertrophic cardiomyopathy (HCM). Panelists voted on the drug’s clinical effectiveness compared […]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. The prescription drugs included on the list increased in net price without sufficient clinical justification and led to an additional $1.67 billion in healthcare […]
ICER Releases Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy Ahead of FDA Approval
The Institute for Clinical and Economic Review (ICER) has released its evidence report for mavacamten, used to treat hypertrophic cardiomyopathy (HCM). The drug targets myosin in cardiac muscle to reduce contraction in the heart, thereby reducing cardiac hypertrophy. Reviewers call for a price tag […]
Panalgo VP Discusses Changes to ICER’s Value Assessments Ahead of Mid-November Webinar
HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried out by the Institute for Clinical and Economic Review (ICER). Real world evidence (RWE) and real world data (RWD) are gaining prominence while the […]
ICER’s Final Evidence Report for Two Myasthenia Gravis Therapies Now Available
The Institute for Clinical and Economic Review (ICER) has published its final evidence report for two drugs used to treat the autoimmune disease Myasthenia Gravis. The report includes cost-effectiveness, efficacy, and value assessments for eculizumab and efgartigimod. “While our review of […]
ICER VP of Research Recognized as Emerging Health Leader, Seeks to Improve Health Equity
Foluso Agboola, a Nigerian researcher who pursued her training at Harvard before joining the Institute for Clinical and Economic Review (ICER), has been recognized by Managed Healthcare Executive as one of 13 rising stars. She’s passionate about drug pricing reform and addressing health […]
